Acquisition: Belluscura PLC (AIM)
Belluscura PLC announced that it has reached an agreement on the terms of a recommended all share offer for TMT Acquisition PLC.
Belluscura PLC (Belluscura) is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies for global markets.
TMT Acquisition PLC (TMT) was established to pursue opportunities in the technology, media and telecom sectors.
In conjunction with Belluscura’s fundraising in October 2023, the acquisition adds a significant injection of working capital into Belluscura, which the Board believes will be sufficient to meet the planned future growth plans of the company.
Crowe's role and team
Crowe provided transactional support to Belluscura on the acquisition, with the Corporate Finance team led by Mitesh Patelia and Ferdia McCarville.
Client quote
“Crowe delivered a high quality report and on time. In particular we appreciated their constructive approach to help ensure that the deal was closed successfully.”
Robert Rauker, Chief Executive Officer, Belluscura PLC
